1.
Soerjomataram I, Lortet-Tieulent J, Parkin DM, et al.: Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet 2012;380:1840-1850.
[PubMed]
https://doi.org/10.1016/S0140-6736(12)60919-2
2.
Hildesheim A, Hadjmichael O, Schwartz P, et al.: Risk factors for rapid onset cervical cancer. Am J Obstet Gynecol 1999;180:571-577.
[PubMed]
https://doi.org/10.1016/S0002-9378(99)70256-5
3.
Liebrich C, Brummer O, Von WR, et al.: Primary cervical cancer truly negative for high-risk human papillomavirus is a rare but distinct entity that can affect virgins and young adolescents. Eur J Gynaecol Oncol 2009;30:45-48.
[PubMed]
4.
Herfs M, Yamamoto Y, Laury A, et al.: A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. Proc Natl Acad Sci U S A 2012;109:10516-10521.
[PubMed]
https://doi.org/10.1073/pnas.1202684109
5.
Arbyn M, Castellsagué X, de Sanjosé S, et al.: Worldwide burden of cervical cancer in 2008. Ann Oncol 2011;22:2675-2686.
[PubMed]
https://doi.org/10.1093/annonc/mdr015
6.
Kocken M, Helmerhorst TJ, Berkhof J, et al.: Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. Lancet Oncol 2011;12:441-450.
[PubMed]
https://doi.org/10.1016/S1470-2045(11)70078-X
7.
Siebert U, Sroczynski G, Hillemanns P, et al.: The German cervical cancer screening model: development and validation of a decision-analytic model for cervical cancer screening in Germany. Eur J Public Health 2006;16:185-192.
[PubMed]
https://doi.org/10.1093/eurpub/cki163
8.
Chao A, Becker TM, Jordan SW, Darling R, Gilli-land FD, Key CR: Decreasing rates of cervical cancer among American Indians and Hispanics in New Mexico (United States). Cancer Causes Control 1996;7:205-213.
[PubMed]
https://doi.org/10.1007/BF00051296
9.
Arbyn M, Ronco G, Anttila A, et al.: Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012;30 (suppl 5):F88-F99.
[PubMed]
https://doi.org/10.1016/j.vaccine.2012.06.095
10.
Ronco G, Dillner J, Elfstrom KM, et al.: Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014;383:524-532.
[PubMed]
https://doi.org/10.1016/S0140-6736(13)62218-7
11.
Meijer CJ, Berkhof H, Heideman DA, Hesselink AT, Snijders PJ: Validation of high-risk HPV tests for primary cervical screening. J Clin Virol 2009;46 (suppl 3):S1-S4.
[PubMed]
https://doi.org/10.1016/S1386-6532(09)00540-X
12.
Petry KU, Böhmer G, Iftner T, Davies P, Brummer O, Kühnle H: Factors associated with an increased risk of prevalent and incident grade III cervical intraepithelial neoplasia and invasive cervical cancer among women with Papanicolaou tests classified as grades I or II cervical intraepithelial neoplasia. Am J Obstet Gynecol 2002;186:28-34.
[PubMed]
https://doi.org/10.1067/mob.2002.118918
13.
Petry KU, Breugelmans JG, Benard S, Lamure E, Littlewood KJ, Hillemanns P: Cost of screening and treatment of cervical dyskaryosis in Germany. Eur J Gynaecol Oncol 2008;29:345-349.
[PubMed]
14.
TOMBOLA Group: Options for managing low grade cervical abnormalities detected at screening: cost effectiveness study. BMJ 2009;339:b2549.
[PubMed]
https://doi.org/10.1136/bmj.b2549
15.
Moss EL, Arbyn M, Dollery E, et al.: European Federation of Colposcopy quality standards Delphi consultation. Eur J Obstet Gynecol Reprod Biol 2013;170:255-258.
[PubMed]
https://doi.org/10.1016/j.ejogrb.2013.06.032
16.
Cuzick J, Clavel C, Petry KU, et al.: Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006;119:1095-1101.
[PubMed]
https://doi.org/10.1002/ijc.21955
17.
Petry KU, Menton S, Menton M, et al.: Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br J Cancer 2003;88:1570-1577.
[PubMed]
https://doi.org/10.1038/sj.bjc.6600918
18.
Sawaya GF, McConnell KJ, Kulasingam SL, et al.: Risk of cervical cancer associated with extending the interval between cervical-cancer screenings. N Engl J Med 2003;349:1501-1509.
[PubMed]
https://doi.org/10.1056/NEJMoa035419
19.
Arbyn M, Kyrgiou M, Simoens C, et al.: Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ 2008;337:a1284.
[PubMed]
https://doi.org/10.1136/bmj.a1284
20.
Petry KU, Rinnau F, Bohmer G, et al.: Annual Papanicolaou screening for 5 years among human papillomavirus-negative women. BMC Cancer 2013;13:379.
[PubMed]
https://doi.org/10.1186/1471-2407-13-379
21.
McCredie MR, Sharples KJ, Paul C, et al.: Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008;9:425-434.
[PubMed]
https://doi.org/10.1016/S1470-2045(08)70103-7
22.
Petry KU: Management options for cervical intraepithelial neoplasia. Best Pract Res Clin Obstet Gynaecol 2011;25:641-651.
[PubMed]
https://doi.org/10.1016/j.bpobgyn.2011.04.007
23.
Luyten A, Scherbring S, Reinecke-Luthge A, et al.: Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany - experience over 3 years. J Clin Virol 2009;46(suppl 3):S5-10.
[PubMed]
https://doi.org/10.1016/S1386-6532(09)70294-X
24.
Gesellschaft der epidemiologischen Krebsregister in Deutschland/Robert Koch-Institut: Krebs in Deutschland 2009-2010, Häufigkeiten und Trends, ed 9. Berlin, 2013. www.ekr.med.uni-erlangen.de/GEKID/Doc/krebs_in_deutschland_2009_2010.pdf.
[PubMed]
https://doi.org/10.3109/0284186X.2012.708105
25.
Gesellschaft der epidemiologischen Krebsregister in Deutschland/Robert Koch-Institut: Krebs in Deutschland 2005-2006, Häufigkeiten und Trends, ed 7. Berlin, 2010.
26.
Chen T, Jansen L, Gondos A, et al.: Survival of cervical cancer patients in Germany in the early 21st century: a period analysis by age, histology, and stage. Acta Oncol 2012;51:915-921.
27.
Traut HF, Papanicolaou GN: Cancer of the uterus: the vaginal smear in its diagnosis. Cal West Med 1943;59:121-122.
[PubMed]
28.
Moyer VA: Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012;156:880-891.
[PubMed]
https://doi.org/10.7326/0003-4819-156-12-201206190-00424
29.
Whitlock E P, Vesco KK, Eder M, et al.: Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2011;155:687-697.
[PubMed]
https://doi.org/10.7326/0003-4819-155-10-201111150-00376
30.
Sankaranarayanan R, Nene MB, Shastri SS, et al.: HPV Screening for cervical cancer in rural India. N Engl J Med 2009;360:1385-1394.
[PubMed]
https://doi.org/10.1056/NEJMoa0808516
31.
Arbyn M, Raifu AO, Weiderpass E, et al.: Trends of cervical cancer mortality in the member states of the European Union. Eur J Cancer 2009;45:2640-2648.
[PubMed]
https://doi.org/10.1016/j.ejca.2009.07.018
32.
Wörmann B: Zervixkarzinom: Systemische Therapie in einem kurativen multimodalen Konzept. Onkologe 2012;18:56-60.
https://doi.org/10.1007/s00761-011-2189-3
33.
Anttila A, Pokhrel A, Kotaniemi-Talonen L, et al.: Cervical cancer patterns with automation-assisted and conventional cytological screening: a randomized study. Int J Cancer 2011;128:1204-1212.
[PubMed]
https://doi.org/10.1002/ijc.25677
34.
Petry KU: Sekundärprävention des Zervixkarzinoms. Onkologe 2012;18:27-34.
https://doi.org/10.1007/s00761-011-2098-5
35.
Hellsten C, Sjöström K, Lindqvist PG: A 2-year follow-up study of anxiety and depression in women referred for colposcopy after an abnormal cervical smear. BJOG 2008;115:212-218.
[PubMed]
https://doi.org/10.1111/j.1471-0528.2007.01609.x
36.
Müller H: Modernes Gesundheitsmanagement und physische Anthropologie. Bulletin der Schweizerischen Gesellschaft für Anthropologie 2010;16:35-46.
37.
Kyrgiou M, Arbyn N, Martin-Hirsch P, et al.: Increased risk of preterm birth after treatment for CIN. BMJ 2012;345:e5847.
[PubMed]
https://doi.org/10.1136/bmj.e5847
38.
AWMF S2 Leitlinie: Zervixkarzinom. Interdisziplinäre Leitlinie zur Diagnostik und Therapie des Zervixkarzinoms, 2008. www.awmf.org/uploads/tx_szleitlinien/032-033l_S2k_Zervixkarzinom-ung.pdf.
39.
Schiffman M, Castle PE, Jeronimo J, et al.: Human papillomavirus and cervical cancer. Lancet 2007; 370:890-907.
[PubMed]
https://doi.org/10.1016/S0140-6736(07)61416-0
40.
Bosch FX, Broker TR, Forman D, et al.: Comprehensive control of human papillomavirus infections and related diseases. Vaccine 2013;315:H1-H31.
[PubMed]
https://doi.org/10.1016/j.vaccine.2013.10.003
41.
Crosbie EJ, Einstein MH, Franceschi S, et al.: Human papillomavirus and cervical cancer. Lancet 2013;382:889-899.
[PubMed]
https://doi.org/10.1016/S0140-6736(13)60022-7
42.
Walboomers JM, Jacobs MV, Manos MM: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19.
[PubMed]
https://doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
43.
Guan P, Howell-Jones R, Li N, et al.: Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer 2012;131:2349-2359.
[PubMed]
https://doi.org/10.1002/ijc.27485
44.
Brotherton JM, Fridman M, May CL, et al.: Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an eco-logic study. Lancet 2011;377:2085-2092.
[PubMed]
https://doi.org/10.1016/S0140-6736(11)60551-5
45.
Schiffman M, Solomon D: Cervical-cancer screening with human papillomavirus and cytologic contesting. N Engl J Med 2013;369:2324-2331.
[PubMed]
https://doi.org/10.1056/NEJMcp1210379
46.
Dillner J, Rebolj M, Birembaut P, et al.: Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008;337:a1754.
[PubMed]
https://doi.org/10.1136/bmj.a1754
47.
Sroczynski G, Schnell-Inderst P, Mühlberger N, et al.: Cost-effectiveness of primary HPV screening for cervical cancer in Germany - a decision analysis. Eur J Cancer 2011;47:1633-1646.
[PubMed]
https://doi.org/10.1016/j.ejca.2011.03.006
48.
Schenck U, von Karsa L: Cervical cancer screening in Germany. Eur J Cancer 2000;36:2221-2226.
[PubMed]
https://doi.org/10.1016/S0959-8049(00)00313-0
49.
Arbyn M, Anttila A, Jordan J, et al.: European Guidelines for Quality Assurance in Cervical Cancer Screening. Second edition - summary document. Ann Oncol 2010;21:448-458.
[PubMed]
https://doi.org/10.1093/annonc/mdp471
50.
Schneider A, Kraus H, Schuhmann R, Gissmann L: Papillomavirus infection of the lower genital tract: detection of viral DNA in gynecological swabs. Int J Cancer 1985;35:443-448.
[PubMed]
https://doi.org/10.1002/ijc.2910350405
51.
De Villiers EM, Wagner D, Schneider A, Wesch H, Miklaw H, Wahrendorf J, Papendick U, zur Hausen H: Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy. Lancet 1987;2:703-706.
52.
Ikenberg H, Bergeron C, Schmidt D, Griesser H, Alameda F, Angeloni C, Bogers J, Dachez R, Denton K, Hariri J, Keller T, von Knebel Doeberitz M, Neumann HH, Puig-Tintore LM, Sideri M, Rehm S, Ridder R; PALMS Study Group: Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study. J Natl Cancer Inst 2013;105:1550-1557.
[PubMed]
https://doi.org/10.1093/jnci/djt235
53.
Uijterwaal MH, Witte BI, van Kemenade FJ, Rijkaart D, Ridder R, Berkhof J, Balfoort-van der Meij GA, Bleeker MC, Snijders PJ, Meijer CJ: Triaging borderline/mild dyskaryotic Pap cytology with p16/Ki-67 dual-stained cytology testing: cross-sectional and longitudinal outcome study. Br J Cancer 2014;110:1579-1586.
[PubMed]
https://doi.org/10.1038/bjc.2014.34
54.
Petry KU, Luyten, Scherbring S: Accuracy of colposcopy management to detect CIN3 and invasive cancer in women with abnormal screening tests: results from a primary HPV screening project from 2006 to 2011 in Wolfsburg, Germany. Gynecol Oncol 2013;128:282-287.
[PubMed]
https://doi.org/10.1016/j.ygyno.2012.10.017
55.
No authors listed: Screening for squamous cervical cancer: duration of low risk after negative results of cervical cytology and its implication for screening policies. IARC Working Group on evaluation of cervical cancer screening programs. Br Med J 1986;293:659-664.
[PubMed]
56.
Bogaards JA, Coupe VM, Xiridou M, Meijer CJ, Wallinga J, Berkhof J: Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence. Epidemiology 2011;22:505-515.
[PubMed]
https://doi.org/10.1097/EDE.0b013e31821d107b
57.
Bettigole C: The thousand-dollar Pap smear. N Engl J Med 2013;369:1486-1487.
[PubMed]
https://doi.org/10.1056/NEJMp1307295
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently...
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2014
You do not currently have access to this content.